Home » Topics » BioWorld Science

BioWorld Science
RSS

Positive interim safety data presented from ongoing phase Ib/IIa study of ATYR-1923

Dec. 13, 2019

Phase Ib data for carfilzomib plus chemotherapy in children with refractory ALL

Dec. 13, 2019

EGFL7 as a new therapeutic target in AML

Dec. 13, 2019

TDP-43-mediated splicing repression as a therapeutic target for ALS-FTD

Dec. 13, 2019

Phase I data presented for the novel M1 mAChR modulator VU-319

Dec. 13, 2019

Manageable safety and activity seen with GDC-0077 combination treatments in phase Ib study

Dec. 13, 2019

Improbability research yields path to HIV vaccine

Dec. 13, 2019

Emergex advances early development of vaccine candidate against F. tularensis

Dec. 12, 2019

Transgene opens enrollment in phase I study of TG-4050 for ovarian cancer

Dec. 12, 2019

Xintela's function-blocking antibody suppresses growth of glioblastoma tumors in preclinical model

Dec. 12, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...